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Objectives
The aim of this study was to determine whether a new percutaneous mechanical circulatory support (pMCS) device (Impella CP, Abiomed, Danvers, Massachusetts) decreases 30-day mortality when compared with an intraaortic balloon pump (IABP) in patients with severe shock complicating AMI.
Methods
In a randomized, prospective, open-label, multicenter trial, 48 patients with severe CS complicating AMI were assigned to pMCS (n = 24) or IABP (n = 24). Severe CS was defined as systolic blood pressure <90 mm Hg or the need for inotropic or vasoactive medication and the requirement for mechanical ventilation. The primary endpoint was 30-day all-cause mortality.
Results
At 30 days, mortality in patients treated with either IABP or pMCS was similar (50% and 46%, respectively; hazard ratio with pMCS: 0.96; 95% confidence interval: 0.42 to 2.18; p = 0.92). At 6 months, mortality rates for both pMCS and IABP were 50% (hazard ratio: 1.04; 95% confidence interval: 0.47 to 2.32; p = 0.923).
Conclusions
In this explorative randomized controlled trial involving mechanically ventilated patients with CS after AMI, routine treatment with pMCS was not associated with reduced 30-day mortality compared with IABP.
Despite advances in treatment, mortality in acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains high.
1-4 Short-term mechanical circulatory support devices can be deployed to support the endangered circulation. Intra-aortic balloon counterpulsation (IABP) has been the most widely used mechanical circulatory support device for decades. 5 A meta-analysis of smaller-sized studies and a large randomized controlled trial did not show a beneficial effect of IABP in the setting of CS after AMI. 4, 6, 7 Today, IABP usage has a Class IIb recommendation in American guidelines and a Class III recommendation in European guidelines. [8] [9] [10] [11] The lack of efficacy of the IABP is likely to be, at least partly, the reason for the observed increased usage of more potent mechanical circulatory devices.
5,12
The percutaneous Impella platform (Abiomed, Danvers, Massachusetts) consists of the Impella 2.5 (maximum output 2.5 l/min) and Impella CP (maximum output around 3.7 l/ min). It has been shown that Impella support in the acute situation is feasible and provides greater hemodynamic support when compared with IABP. [13] [14] [15] [16] However, neither of the 2 small randomized trials in patients with AMI had enough power to show differences in clinical outcomes, and 1 was prematurely stopped. 15, 16 The IMPRESS in Severe Shock (IMPella versus IABP Reduces mortality in STEMI patients treated with primary PCI in Severe cardiogenic SHOCK) trial is an exploratory assessment of mortality and other safety outcomes comparing percutaneous mechanical circulatory support (pMCS) by the Impella CP with IABP in mechanically ventilated patients with CS in AMI.
METHODS

Study design
The Academic Medical Center in Amsterdam designed and sponsored this multicenter, open-label, and randomized trial. Trial administration, data management, and statistical analysis were performed by the sponsor. The executive committee had unrestricted access to the data, and the authors analyzed the data and prepared the paper. The trial design was approved by the ethics committee at each participating center. The ethics committee waived the requirements for written informed consent before randomization to prevent treatment delay in patients who were in imminent danger of death. The requirement for obtaining informed consent to use the data varied depending on local ethical requirements. Informed consent was obtained from the legal representative without any undue delay. Alternatively, informed consent was obtained after recovery (and therefore, no informed consent was obtained in patients who died). An independent data and safety monitoring board and the ethics committees reviewed the interim results after each 10 included patients. During the inclusion period of the trial, the European Society of Cardiology guidelines for routine use of the IABP changed from Class II (may be considered) to Class III (not recommended) 10 . The ethics committees were notified of this change and approved continuation of the trial. The study was conducted in accordance with the provisions of the Declaration of Helsinki as amended in Edinburgh, Scotland.
17
Patients
Patients were eligible for the trial if they presented with an AMI with ST-segment elevation complicated by severe CS in the setting of immediate percutaneous coronary intervention (PCI). Severe CS was defined as a systolic blood pressure <90 mmHg for longer than 30 min or the need for inotropes or vasopressors to maintain a systolic blood pressure >90 mm Hg. To select a patient population in even worse condition, patients only qualified if they were mechanically ventilated before randomization. Exclusion criteria were: severe aorto-iliac arterial disease impeding placement of either IABP or pMCS, known severe cardiac aortic valvular disease, serious known concomitant disease with a life expectancy of <1 year, known participation in this study or any other trial within the previous 30 days, or coronary artery bypass grafting within the preceding week.
Treatment
Eligible patients were assigned to treatment with pMCS by Impella CP with IABP (control group). Randomization was performed in a 1:1 ratio using an internet-based application. The moment of initiation of pMCS or IABP (before, during, or immediately after the PCI) was at the discretion of the treating physician. To achieve equal initiation of therapy for both groups, timing of randomization was equal to pMCS or IABP placement: immediately before, during, or after PCI. All patients underwent primary PCI. In multivessel disease, the mode of revascularization (immediate or staged PCI of the nonculprit lesions) was left to the discretion of the operator. Duration of mechanical support was left to the discretion of the treating physician, and IABP or the pMCS device was extracted in accordance with daily clinical routine. Weaning was achieved by reduction of the trigger ratio (IABP) or amount of support (pMCS). Per protocol, crossover was not allowed; however, it did occur.
Outcomes
The primary study endpoint was 30-day all-cause mortality. The secondary endpoint was 6-month mortality. Descriptive endpoints included duration of mechanical ventilation; the need for and duration of inotropic and vasopressor therapy; renal replacement therapy; length of hospital stay; the amount of blood products needed; additional treatments, such as ICD placement and the need for surgical left ventricular assist device (LVAD) placement or heart transplantation; the occurrence of stroke, myocardial reinfarction, repeat PCI, coronary artery bypass grafting, major vascular complications, major bleeding, or hemolysis requiring extraction of the IABP or pMCS; device failure requiring extraction of the pMCS or IABP; and rehospitalization. Definitions can be found in the supplementary file. An independent clinical event committee adjudicated the events. Imaging parameters were assessed by independent local core laboratories that were blinded to the other trial data and randomization outcome (Supplementary data).
Statistical analysis
On the basis of previous studies and our experience that survival is <10% in patients with severe shock, we assumed that treatment with pMCS would decrease the absolute 30-day mortality rate from 95% to 60%. On the basis of this assumption, a trial with 24 patients in each group would achieve 80% power, with a 2-sided alpha of 5%. The protocol allowed for a sample-size re-estimation after inclusion of 32 patients. At the interim analysis, mortality in the control group was much lower than anticipated, and there was no difference in mortality between the treatment groups. Therefore, adaptation of the sample size was not meaningful, and the Executive Committee decided to complete the study with 48 patients as an exploratory safety study. All data were analyzed according to the intention-to-treat principle. In addition, a per-protocol analysis of the primary endpoint was performed. Cumulative mortality throughout the first 6 months following randomization was characterized with the use of Kaplan-Meier plots, with the log-rank test used for the comparison between the 2 groups. Descriptive endpoints and clinical course variables were not statistically tested because they are highly influenced by the number of deceased patients in both groups. Additional comparisons were made according to vital status at 30 days. Differences were assessed with the Fisher exact test or the chi-square test for binary endpoints and a Mann-Whitney U test for quantitative endpoints. A post hoc subgroup analysis was performed in subgroups defined according to age (<75 or >75 years), sex, time to return of spontaneous circulation (ROSC) (>20 or <20 min), lactate level >7.5 or <7.5 mmol/l, TIMI (Thrombolysis In Myocardial Infarction) flow post-PCI, systolic blood pressure before IABP or pMCS placement (>80 or <80 mm Hg), and the presence or absence of traumatic injuries on admission.
RESULTS
Patients
Between June 1, 2012, and September 15, 2015, a total of 48 patients were randomly assigned to either pMCS therapy (n ¼ 24) or IABP (n ¼ 24) (Figure 1 ). The baseline characteristics of the 2 groups were well balanced ( (21 IABP and 20 Impella) , Hemoglobin (22 IABP and 21 Impella) , Creatinine (23 IABP and 23 Impella) , Glucose (23 IABP and 20 Impella), pH (16 IABP and 20 Impella) 
Treatment
Randomization and placement of the pMCS or IABP took place after revascularization except for 8 patients in whom IABP or the pMCS was initiated before revascularization (3 in the IABP group and 5 in the pMCS group) ( Table 2 ). The infarct related artery was the left anterior descending (LAD) in the majority of the patients (65%) and 98% of the patients were treated with stent placement. The median duration of circulatory support was 48 h (IABP) and 49 h (pMCS). All patients were treated with catecholamines during admission to the intensive care unit, 31% received renal replacement therapy, and 75% were treated with therapeutic hypothermia (Table 3) . Crossover or upgrading to device with more support, n/n (%) † 1/24 (4.2) 3/24 (12.5)
Other support before randomization, n/n (%) ‡ 1/24 (4.2) 0/24 (0)
Mechanical ventilation
Patients treated, n/n (%) 24/24 (100) 24/24 (100) Duration ( Of the patients in the IABP group, 1 patient subsequently received pMCS and was transferred to another hospital for treatment with extracorporeal life support oxygenation. Two patients received an alternative device, the Impella 5.0 (Abiomed, Aachen, Germany), after the IABP treatment, and 1 of them received subsequent extracorporeal life support and an LVAD at another hospital. Of the patients treated with the pMCS, 1 patient subsequently received the Impella 5.0. One patient was already on IABP support before randomization (inserted before the start of the primary PCI) and was randomized after the PCI to pMCS treatment. Formally, this patient constitutes a protocol violation, as IABP therapy before randomization was an exclusion criterion. One patient did not receive pMCS as the patient showed signs of recovery after randomization to receive device therapy.
Outcomes
At 30 days, mortality was similar in patients treated with IABP and pMCS therapy: 50% and 46%, respectively (hazard ratio [HR] with pMCS therapy: 0.96; 95% confidence interval [CI]: 0.42 to 2.18; p = 0.92) ( Table 4) . At 6 months, the mortality rate was 50% in both groups (HR: 1.04; 95% CI: 0.47 to 2.32; p = 0.92). Only minor differences were found in an analysis restricted to the per-protocol population from which 3 patients treated with pMCS were excluded (Supplementary data). The Kaplan-Meier estimates for 6-month mortality in the per-protocol population were 52% in the IABP group and 48% in the pMCS group (HR with pMCS: 0.95; 95% CI: 0.41 to 2.21; p = 0.91). The primary cause of death at 6 months was brain damage (46% of the deceased patients; 6 of 12 in the IABP group and 5 of 12 in the pMCS group). Death due to refractory CS occurred in 29% of the deceased patients (3 of 12 in the IABP vs. 4 of 12 in the pMCS therapy group). In each group, 1 patient experienced an ischemic stroke during support. There was 1 major vascular complication in the pMCS group, a retroperitoneal bleeding after pMCS insertion (the patient had a calcified and stented vascular trajectory, but femoroiliac angiography seemed compatible with pMCS insertion, see Supplementary data for event specifications). There were more bleeding events during admission in the pMCS therapy group than in the IABP group (8 vs. 2, of which 3 and 1, respectively, were adjudicated as IABP or pMCS related). There were 2 patients in whom the presence of hemolysis influenced the decision to stop the pMCS support (in one patient, the pMCS support was stopped due to hemolysis in combination with an improved ejection fraction; and in the other patient, the pMCS was removed after the decision to withhold further therapy due to multiorgan failure, recurrent ventricular arrhythmia, hemolysis, and hemodynamic instability). 
DISCUSSIOn
This is the first randomized trial to compare Impella CP with the IABP in mechanically ventilated patients with CS complicating AMI. pMCS support was not associated with lower 30-day or 6-month mortality when compared with IABP support. Although this trial included only 48 patients, it is thus far the largest trial to randomly compare pMCS and IABP, and it is the only trial to use the Impella CP device. To date, only a few randomized controlled trials have studied mechanical circulatory support in CS, highlighting the logistical and ethical challenges in conducting trials in these patients. In the setting of CS, 2 small trials have been performed with the Impella 2.5 pMCS, both using IABP therapy as the control therapy. The ISAR-SHOCK (Efficacy Study of LV Assist Device to Treat Patients With Cardiogenic Shock) trial randomized 26 patients between IABP and the Impella 2.5 in the setting of CS complicating AMI. The primary endpoint was the difference in cardiac index after 30 min of support, and the trial showed a higher cardiac index in patients treated with Impella than with IABP. Overall mortality was 46% in both groups. 15 The IMPRESS in STEMI trial randomized between the IABP and Impella 2.5 in patients with cardiogenic pre-shock. This study was powered for a difference in left ventricular function. However, this trial was stopped prematurely due to a lack of enrollment after 21 patients had been enrolled.
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In the present trial, we included mechanically ventilated patients with CS. Although the decision to start mechanical ventilation may be arbitrary and the moment of initiation may differ between physicians, it is a marker for worse clinical condition. We have chosen to use this criterion because it is easy to apply, is readily available, and does not require blood sample analysis or additional Swan-Ganz cardiac output measurements. Those inclusion criteria resulted in inclusion of patients with high lactate and low pH levels on admission, and all patients received catecholamines before randomization. Although we did not aim to include resuscitated patients, the inclusion criteria resulted in 92% of enrolled patients having a cardiac arrest prior to randomization. In addition, almost one-half (48%) of the patients had time to ROSC longer than 20 min. Traumatic injuries due to cardiac arrest were frequently present (15%). These criteria identified a unique patient population that is usually excluded from randomized CS clinical trials and resulted in a patient population with a high 30-day mortality rate of 48%. This is higher than in the most recently reported randomized trial on CS (IABPSHOCK II [Intra-Aortic Balloon Counterpulsation in Acute Myocardial Infarction Complicated by Cardiogenic Shock] trial), which reports a mortality of 40% in patients randomized between IABP support and conventional therapy (n = 598). 4 Two previous studies compared IABP and TandemHeart (CardiacAssist Inc., Pittsburgh, Pennsylvania) in CS, with 30-day mortality rates of 44% (n = 41) 18 and 42% (n = 33) 19 . Neither trial observed any difference in mortality between the patients treated with TandemHeart or IABP. A registry reporting on Impella 2.5 versus IABP in the setting of post-cardiac arrest shock reports mortality rates of 77% in patients treated with the device and 79% in patients treated with IABP.
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Two multicenter registries including patients with CS complicating AMI supported with a pMCS showed mortality at discharge of 49.3% (n = 154) and 30-day mortality of 64.2% (n = 120).
21,22
A recent USpella registry analysis submitted to the U.S. Food and Drug Administration for the Impella pre-market approval for use in CS demonstrated a marked difference between patients who were likely to be included in randomized shock trials versus those who were not-the latter of whom resemble the population studied in the present trial. 23 A considerable proportion of patients died due to anoxic brain damage (46%), compared with refractory CS or multiorgan failure (29%), or for other reasons (25%). This high rate of neurologically deceased patients is likely to be the result of the high percentage of resuscitated patients and longer times to ROSC. Nevertheless, our study resembles a real-life cohort in daily clinical practice of patients with CS complicating ST-segment elevation myocardial infarction. In our study, bleeding occurred more often in the pMCS-treated patients than in the IABP-treated patients. During mechanical support, patients receive heparin in addition to standard dual antiplatelet therapy after PCI (aspirin and a P2Y 12 receptor blocker), which makes the occurrence of bleeding more likely, especially in patients with additional traumatic injuries on admission. Higher rates of bleeding in pMCS-treated patients compared with IABP-treated patients were also described in a registry comparing Impella 2.5 and IABP in a post cardiac arrest population (n = 78), which found severe bleeding in 26% of the device patients versus 6% of IABP patients.20 Two large multicenter Impella 2.5 registries describe the rates of bleeding requiring transfusion of 24.2% and 17.5% and the rates of hemolysis as 7.5% and 10.3%. 21, 22 These complication rates are comparable to the pMCS in our study (33.3% bleeding and 8.3% hemolysis). The IABP-SHOCK II trial reports 20.7% bleeding in the IABP patients (and 20.8% in the control group). This is higher than the 8.2% bleeding in our IABP group. Although discouraged, some crossovers and upgrades to other mechanical support therapy did take place: 3 in the IABP group and 1 in the pMCS group. Crossover or upgrading was solely at the discretion of the investigator. There was a trend toward more upgrading/crossover in the IABP group. Upon initiation of our study, IABP therapy was still recommended in the guidelines for CS, but was downgraded to a Class III recommendation in the European guidelines and Class II in the American guidelines during the inclusion period of the study. After consultation with the institutional review board and in the light of the severity of clinical condition with higher mortality rates than in the IABP-SHOCK II study, the control therapy remained unchanged. In addition, after the interim analysis it was clear the study was underpowered to show a difference in mortality at 30 days, and the executive committee allowed it to proceed for exploratory purposes.
Although not adequately powered, our trial suggests that in patients with CS without selection on age, ROSC times, and pre-procedural traumatic injuries, no clear signal of superior outcome was observed in patients with pMCS support when compared with the IABP. There may be several reasons why the pMCS treated patients did not show improved mortality rates. A possible explanation is the unselective nature of the patients included in the study. In our study, 92% of patients had resuscitated cardiac arrest, which implies a prevalence of post-anoxic neurological damage present at the moment of randomization. Any kind of mechanical circulatory support may be of limited clinical utility in these patients. Another explanation might be that CS after AMI is not only a matter of low cardiac output. The shock syndrome also comprises an irreversible damage due to diminished organ perfusion and inflammatory responses. Hence, providing mechanical hemodynamic support may not be enough to reverse the damage that has already occurred. Although the Impella CP can provide up to 3.5 l/min of forward flow, it might still be insufficient to reverse severe CS with advanced end organ failure, especially as in clinical practice, long-term Impella CP support achieves <3.5 l/min hemodynamic support. In this trial, the main rationale for using Impella CP instead of a device that can provide even more hemodynamic support (e.g., Impella 5.0), was the need for a surgical cut-down for implantation. The Impella CP can be inserted percutaneously, which enables quick insertion even before performing primary PCI. Earlier reports have demonstrated a better survival in patients who received a pMCS before primary PCI than in implantation post-PCI. 22 Our data also shows a trend toward lower mortality rates in patients in whom either the device or IABP was initiated before the primary PCI (25.0% vs. 52.5% overall).
Study limitations
A major limitation of this trial is its small number of patients. Adequately powered randomized clinical trials are needed to ascertain the value of pMCS in patients with CS after AMI.
COnCLUSIOnS
In this explorative study, routine treatment with pMCS was not associated with lower 30-day mortality in patients with CS complicating AMI.
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Device failure
Any device failure requiring extraction or replacement of the device. Only randomized device.
Hemolysis requiring extraction of the device
Evidence of clinically relevant hemolysis requiring extraction of the device.
Hospitalization
Re-admission to the hospital for at least one night after discharge from the initial hospitalization.
Major Bleeding
Any of the following: Bleeding with associated serum hemoglobin level decrease of at least 5 g/dL (=3.1 mmol/L). The decrease in hemoglobin will be calculated as the last recorded Hb measurement preceding the onset of the bleeding, subtracted by the nadir Hb measurement (associated with the bleeding). Bleeding necessitating a minimum of 2 packed cells of blood product transfusion (only blood transfusions that are explicitly related to the bleeding are taken into account) The need for surgery to control the bleeding
Major vascular complications
Any of the following: A major bleed arising at the arterial access site (for major bleeding definition see above) requiring extraction of the device A thrombotic occlusion of the femoral artery Limb ischemia requiring extraction of either of the study devices The need for vascular surgery to correct a vascular complication.
Myocardial infarction
Defined by 3rd definition MI 1
Refractory cardiogenic shock
Cardiac and circulatory failure resulting in organ hypo-perfusion unresponsive to medical therapies.
ROSC time
Time from cardiac arrest until return of sustained spontaneous circulation (first sustained ROSC longer than 5 minutes). Estimated if not available.
Stroke
Any stroke confirmed by a neurologist and a concurring CT scan.
Traumatic injuries
Life threatening traumatic injuries acquired before hospitalization. 
Supplement C: Per-protocol analysis
A total of 3 patients were excluded from the pMCS group in the per-protocol analysis. One patient did not receive any mechanical assist devices due to signs of recovery after randomization (pMCS group). Another patient was randomized to pMCS but erroneously an IABP was placed. In a third patient, an IABP was placed during a primary PCI of the left main artery during ongoing CPR. After the primary PCI the patient was randomized to pMCS and received pMCS. However, the patient deceased in the catheterization lab. This was a protocol violation as the patient was already on mechanical support before randomization. p=0.91 by log-rank test
Mortality (%)
Kaplan-Meier curves for all-cause mortality up to 6 months, per protocol analyses. 
Supplement F: Events specification
Cause of death Other reasons: IABP group: one patient had a asystole due to pulmonary embolism. Two patients had respiratory failure. pMCS group: One patient had a retroperitoneal bleeding after pMCS insertion in calcified and stented trajectory. One patient developed a sepsis and one patient had respiratory insuffiency;
Major vascular complication pMCS group: One patient had a retroperitoneal bleeding after pMCS insertion in a calcified and stented trajectory for which surgery was performed. The patient deceased.
Major bleeding IABP group: One patient had a bleeding from puncture site of IABP after removal (device related bleeding) and one patient had a gastro-intestinal bleeding 14 days after IABP removal (non-device related).
pMCS group: Device related: One patient had a retroperitoneal bleeding after pMCS insertion in calcified and stented trajectory. One patient had a bleeding from the pMCS puncture site during pMCS and one patient had a bleeding from the pMCS puncture site after removal of the device. Non-device related: One patient had bleeding from the mouth and from all venous access sites during pMCS support. One patient had diffuse bleeding after multiple trauma from a car accident during pMCS support. One patient had a bleeding from an intercostal artery during pMCS support, and one patient had bleedings form his mouth and lungs during pMCS support. There was one patients who was bleeding from the puncture site for dialysis 11 days after removal of the pMCS.
Hemolysis requiring extraction of the device pMCS group: In one patient the pMCS was stopped due to hemolysis in combination with an improved ejection fraction. In one patient pMCS was removed after the decision to withhold further therapy due to multi-organ failure, recurrent ventricular arrhythmia, hemolysis, and hemodynamic instability.
Surgery pMCS group: One patient had a retroperitoneal bleeding after pMCS insertion in calcified and stented trajectory for which laparotomy was performed. One patient had an intrapleural bleeding due to rib fracture for which coiling of the intercostal artery was performed.
Myocardial (re)infarction IABP group: One patient had an MI related to dissection after additional PCI 3 weeks after the initial MI. One patient had a NSTEMI, 2 days after IABP removal.
pMCS group: Myocardial infarction after 3 days, secondary to ischemic imbalance.
Re-hospitalization IABP group: Pneumonia.
pMCS group: One patient was admitted with congestive heart failure requiring mechanical ventilation. One patients was hospitalized multiple times with an atrial flutter.
One patients was hospitalized due to hyperventilation. One patient was readmitted with incomplete healing of the groin resulting in leg ischemia for which thrombectomy was performed (pMCS leg, 40 days after pMCS removal. One patient was hospitalized due to bacteremia associated with a central venous catheter infection used for dialysis.
Stroke
IABP group: Ischemic stroke with hemorrhagic conversion on same day as initial MI, during IABP support.
pMCS group: Ischemic stroke 2 days after initial MI, during pMCS support.
Supplement G: Weaning
Weaning was left to the attending physicians at the intensive care unit. pMCS performance was set to a maximum level without console alarms (usually position or suction). Weaning was typically started usually 12-24 hours after PCI upon hemodynamic recovery allowing reduction of the inotropes and vasopressors in combination with echocardiography when needed. Weaning usually occurred in two steps. From maximum possible support (P7-8) to more or less half support (P4-5) and if needed patient were observed a couple of hours (typically overnight with Impella support P2-3) on low levels before device removal.
